ibrutinib,zilovertamab
oncternal therapeutics,abbvie,janssen
['zilovertamab', 'cll', ' ibru', 'nhl', 'lymphoma']
jtcc s studied zilovertamab with ibrutinib for mcl, cll and other lymphomas. they've shown great activity in b-cell nhl and cll. the goal is to study effectiveness in combining with other agents such as btk inhibitors. #ash2022 #mcl #cll 
John Theurer Cancer Center @HackensackUMC is among the nation's top cancer hospitals with 14 specialized divisions providing the most advanced care possible.